laszlo vecsei (39 risultati)

Condizione: New.

Hardback. Condizione: New.

Condizione: New.

Condizione: New.

Condizione: New.

Condizione: New. In.

Condizione: New.

Condizione: New. pp. 208.

Condizione: New.

Condizione: New. pp. 212.

Hardback. Condizione: New.

Buch. Condizione: Neu. Neuware -Over the last decade, the considerable progress made in biochemistry, molecular biology, genetics and neuropharmacology has revealed some ofthe intimate mechanisms ofthe neurodegenerative disorders. There is increasing evidence linking genetic defects affecting mitochondria to Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease and some other neurological disorders. Advances in knowledge are fueled through improved animal models that use mitochondrial toxins, excitotoxins, and transgenic animals. Therapeutic studies in these models have strengthened the possibility for effective treatments in man. By defining the pathomechanisms, we hope to be in the position to prevent cell death by protecting neurons. Indeed serious preclinical and clinical research is going on in the field of neuroprotection in stroke, Parkinson's disease, epilepsy, demyelinating disorders and dementia. Based on these scientific ideas, the Symposium in honour of Professor Abel Lajtha was organized by the European Society for ClinicalNeuropharmacology(ESCNP) and the Danube Symposium for Neurological Sciences in Budapest, Hungary, October 24-25, 2002. Professor Lajtha was born in Budapest in 1922 and his home town is an ideal venue for strengthening the bonds between Western and Eastern European Neuroscientists. Professor Peter Riederer (Wurzburg) held the 2002 special 'Dezso Miskolczy Memorial Lecture' in Abel Lajtha's Honour. Thanks are due to the invited speakersofthis Symposium for their excellentcontribution. Laszlo Vecsei vii CONTENTS Advances in Neuroprotection Research for Neurodegenerative Diseases 1 Mario E. Gotz and Peter Riederer Neurotransmitter Release in Experimental Stroke Models: The Role of Glutamate-GABA Interaction 21 Laszlo G. Harsing, Jr.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 210 pp. Englisch.

Taschenbuch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - Over the last decade, the considerable progress made in biochemistry, molecular biology, genetics and neuropharmacology has revealed some ofthe intimate mechanisms ofthe neurodegenerative disorders. There is increasing evidence linking genetic defects affecting mitochondria to Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease and some other neurological disorders. Advances in knowledge are fueled through improved animal models that use mitochondrial toxins, excitotoxins, and transgenic animals. Therapeutic studies in these models have strengthened the possibility for effective treatments in man. By defining the pathomechanisms, we hope to be in the position to prevent cell death by protecting neurons. Indeed serious preclinical and clinical research is going on in the field of neuroprotection in stroke, Parkinson's disease, epilepsy, demyelinating disorders and dementia. Based on these scientific ideas, the Symposium in honour of Professor Abel Lajtha was organized by the European Society for ClinicalNeuropharmacology(ESCNP) and the Danube Symposium for Neurological Sciences in Budapest, Hungary, October 24-25, 2002. Professor Lajtha was born in Budapest in 1922 and his home town is an ideal venue for strengthening the bonds between Western and Eastern European Neuroscientists. Professor Peter Riederer (Wurzburg) held the 2002 special 'Dezso Miskolczy Memorial Lecture' in Abel Lajtha's Honour. Thanks are due to the invited speakersofthis Symposium for their excellentcontribution. Laszlo Vecsei vii CONTENTS Advances in Neuroprotection Research for Neurodegenerative Diseases 1 Mario E. Gotz and Peter Riederer Neurotransmitter Release in Experimental Stroke Models: The Role of Glutamate-GABA Interaction 21 Laszlo G. Harsing, Jr.

Buch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - Over the last decade, the considerable progress made in biochemistry, molecular biology, genetics and neuropharmacology has revealed some ofthe intimate mechanisms ofthe neurodegenerative disorders. There is increasing evidence linking genetic defects affecting mitochondria to Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease and some other neurological disorders. Advances in knowledge are fueled through improved animal models that use mitochondrial toxins, excitotoxins, and transgenic animals. Therapeutic studies in these models have strengthened the possibility for effective treatments in man. By defining the pathomechanisms, we hope to be in the position to prevent cell death by protecting neurons. Indeed serious preclinical and clinical research is going on in the field of neuroprotection in stroke, Parkinson's disease, epilepsy, demyelinating disorders and dementia. Based on these scientific ideas, the Symposium in honour of Professor Abel Lajtha was organized by the European Society for ClinicalNeuropharmacology(ESCNP) and the Danube Symposium for Neurological Sciences in Budapest, Hungary, October 24-25, 2002. Professor Lajtha was born in Budapest in 1922 and his home town is an ideal venue for strengthening the bonds between Western and Eastern European Neuroscientists. Professor Peter Riederer (Wurzburg) held the 2002 special 'Dezso Miskolczy Memorial Lecture' in Abel Lajtha's Honour. Thanks are due to the invited speakersofthis Symposium for their excellentcontribution. Laszlo Vecsei vii CONTENTS Advances in Neuroprotection Research for Neurodegenerative Diseases 1 Mario E. Gotz and Peter Riederer Neurotransmitter Release in Experimental Stroke Models: The Role of Glutamate-GABA Interaction 21 Laszlo G. Harsing, Jr.

Condizione: As New. Unread book in perfect condition.

Hardcover. Condizione: Like New. Like New. book.

Paperback. Condizione: Like New. Like New. book.

Condizione: As New. Unread book in perfect condition.

Condizione: New. Num Pages: 211 pages, Illustrations. BIC Classification: MJN. Category: (P) Professional & Vocational. Dimension: 269 x 183 x 20. Weight in Grams: 620. . 2006. 1st Edition. Hardcover. . . . .

Gebunden. Condizione: New. Focuses on the metabolism, analytical chemistry and role of kynurenine metabolites in different disorders of the central nervous system. This book discusses neurodegenerative models and pharmacological investigations with kynurenine metabolites and possible.

Condizione: New. Num Pages: 211 pages, Illustrations. BIC Classification: MJN. Category: (P) Professional & Vocational. Dimension: 269 x 183 x 20. Weight in Grams: 620. . 2006. 1st Edition. Hardcover. . . . . Books ship from the US and Ireland.

Buch. Condizione: Neu. Neuware - This book focuses on the metabolism, analytical chemistry and role of kynurenine metabolites in different disorders of the central nervous system. Furthermore, neurodegenerative models and pharmacological investigations with kynurenine metabolites and possible therapeutic perspectives are discussed.

Hardcover. Condizione: new. Hardcover. Migraine is a prevalent and burdensome neurological disorder characterized by throbbing headaches, sensory disturbances, nausea, and sensitivity to light and sound. Due to its severe symptoms and limited treatment options, migraines place a significant burden on people, society, and the economy. The pathophysiology of migraine involves a complex interplay of genetic, environmental, and neurobiological factors. Recent advancements in migraine research have highlighted the significance of experimental models in unraveling the molecular and cellular pathways underlying migraine attacks. This Special Issue delves into cutting-edge research on migraine neuroscience, focusing on experimental models and therapeutic targets to enhance our understanding of migraine pathophysiology and improve patient outcomes. The ultimate goal is to develop targeted therapies that effectively manage migraine symptoms and alleviate the impact of this disorder on individuals' quality of life. Bridging the gap between basic science discoveries and clinical applications remains challenging, necessitating interdisciplinary collaborations and the integration of diverse fields such as neuroscience, genetics, and pharmacology. Leveraging advanced technologies is crucial in identifying novel therapeutic strategies and potential targets for migraine treatment. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.

Buch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Over the last decade, the considerable progress made in biochemistry, molecular biology, genetics and neuropharmacology has revealed some ofthe intimate mechanisms ofthe neurodegenerative disorders. There is increasing evidence linking genetic defects affecting mitochondria to Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease and some other neurological disorders. Advances in knowledge are fueled through improved animal models that use mitochondrial toxins, excitotoxins, and transgenic animals. Therapeutic studies in these models have strengthened the possibility for effective treatments in man. By defining the pathomechanisms, we hope to be in the position to prevent cell death by protecting neurons. Indeed serious preclinical and clinical research is going on in the field of neuroprotection in stroke, Parkinson's disease, epilepsy, demyelinating disorders and dementia. Based on these scientific ideas, the Symposium in honour of Professor Abel Lajtha was organized by the European Society for ClinicalNeuropharmacology(ESCNP) and the Danube Symposium for Neurological Sciences in Budapest, Hungary, October 24-25, 2002. Professor Lajtha was born in Budapest in 1922 and his home town is an ideal venue for strengthening the bonds between Western and Eastern European Neuroscientists. Professor Peter Riederer (Wurzburg) held the 2002 special 'Dezso Miskolczy Memorial Lecture' in Abel Lajtha's Honour. Thanks are due to the invited speakersofthis Symposium for their excellentcontribution. Laszlo Vecsei vii CONTENTS Advances in Neuroprotection Research for Neurodegenerative Diseases 1 Mario E. Gotz and Peter Riederer Neurotransmitter Release in Experimental Stroke Models: The Role of Glutamate-GABA Interaction 21 Laszlo G. Harsing, Jr. 210 pp. Englisch.

Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Over the last decade, the considerable progress made in biochemistry, molecular biology, genetics and neuropharmacology has revealed some ofthe intimate mechanisms ofthe neurodegenerative disorders. There is increasing evidence linking genetic defects affecting mitochondria to Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease and some other neurological disorders. Advances in knowledge are fueled through improved animal models that use mitochondrial toxins, excitotoxins, and transgenic animals. Therapeutic studies in these models have strengthened the possibility for effective treatments in man. By defining the pathomechanisms, we hope to be in the position to prevent cell death by protecting neurons. Indeed serious preclinical and clinical research is going on in the field of neuroprotection in stroke, Parkinson's disease, epilepsy, demyelinating disorders and dementia. Based on these scientific ideas, the Symposium in honour of Professor Abel Lajtha was organized by the European Society for ClinicalNeuropharmacology(ESCNP) and the Danube Symposium for Neurological Sciences in Budapest, Hungary, October 24-25, 2002. Professor Lajtha was born in Budapest in 1922 and his home town is an ideal venue for strengthening the bonds between Western and Eastern European Neuroscientists. Professor Peter Riederer (Wurzburg) held the 2002 special 'Dezso Miskolczy Memorial Lecture' in Abel Lajtha's Honour. Thanks are due to the invited speakersofthis Symposium for their excellentcontribution. Laszlo Vecsei vii CONTENTS Advances in Neuroprotection Research for Neurodegenerative Diseases 1 Mario E. Gotz and Peter Riederer Neurotransmitter Release in Experimental Stroke Models: The Role of Glutamate-GABA Interaction 21 Laszlo G. Harsing, Jr. 208 pp. Englisch.

Condizione: New. Print on Demand.

Condizione: New. PRINT ON DEMAND.

Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Advances in Neuroprotection Research for Neurodegenerative Diseases.- Neurotransmitter Release in Experimental Stroke Models: The Role of Glutamate-GABA Interaction.- Neuroprotection in Ischemic/Hypoxic Disorders: From the Preclinical to the Clinical Testin.

Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Advances in Neuroprotection Research for Neurodegenerative Diseases.- Neurotransmitter Release in Experimental Stroke Models: The Role of Glutamate-GABA Interaction.- Neuroprotection in Ischemic/Hypoxic Disorders: From the Preclinical to the Clinical Testin.

Buch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Migraine is a prevalent and burdensome neurological disorder characterized by throbbing headaches, sensory disturbances, nausea, and sensitivity to light and sound. Due to its severe symptoms and limited treatment options, migraines place a significant burden on people, society, and the economy. The pathophysiology of migraine involves a complex interplay of genetic, environmental, and neurobiological factors. Recent advancements in migraine research have highlighted the significance of experimental models in unraveling the molecular and cellular pathways underlying migraine attacks. This Special Issue delves into cutting-edge research on migraine neuroscience, focusing on experimental models and therapeutic targets to enhance our understanding of migraine pathophysiology and improve patient outcomes. The ultimate goal is to develop targeted therapies that effectively manage migraine symptoms and alleviate the impact of this disorder on individuals' quality of life. Bridging the gap between basic science discoveries and clinical applications remains challenging, necessitating interdisciplinary collaborations and the integration of diverse fields such as neuroscience, genetics, and pharmacology. Leveraging advanced technologies is crucial in identifying novel therapeutic strategies and potential targets for migraine treatment.